␤-cell proliferation in cell lines or animal models. Although these hormones have not yet been tested in the clinic, this approach may lead to the development of a new class of antidiabetic drugs.
Ghrelin is a 28-amino acid stomach-derived peptide hormone bearing a unique acyl modification on the third Ser residue, which is essential for binding to its receptor (18) . We (13) previously reported that exogenous ghrelin administration prevents the development of diabetes at the adult stage of a rat neonate streptozotocin (STZ) model. In that study, we observed increased numbers of phospho-histone H3 ϩ /insulin ϩ cells in the islets of ghrelintreated rats, suggesting that ghrelin had enhanced ␤-cell proliferation. However, it was not clear whether that was a direct or indirect effect of ghrelin treatment. Because ghrelin strongly stimulates GH secretion (18, 27) and food intake (20, 25) , we could not rule out the possibilities that elevated GH or nutritional status may have affected ␤-cell proliferation (6) .
Here, we directly examined the effects of ghrelin on ␤-cells after STZ treatment by using a recently developed rat insulin II promoter-ghrelin internal ribosomal sequence ghrelin O-acyltransferase (GOAT) transgenic (RIP-GG Tg) mice, in which ghrelin and GOAT genes are overexpressed in pancreatic ␤-cells under the control of the rat insulin II promoter (2) . Compared with control mice, RIP-GG Tg mice display an ϳ16-fold increase in pancreatic ghrelin concentrations but no change in plasma ghrelin levels when fed a medium-chain triglyceride-rich diet (MCTD) (2) . The aim of this study was to determine whether ghrelin directly stimulated the proliferation of ␤-cells after STZ-induced injury.
MATERIALS AND METHODS

RIP-GG Tg mice.
RIP-GG Tg mice were generated as reported previously (2) . In this study, we used male heterozygous Tg mice along with their non-Tg littermates as controls. Animals were maintained on a 12:12-h light-dark cycle and fed a standard diet (SD; CE-2, 352 kcal/100 g; Japan CLEA, Tokyo, Japan) or an MCTD containing 45% Dermol M5 (C8:60%, C10:40%; Research Diet, New Brunswick, NJ) as indicated. RIP-GG Tg mice showed elevated pancreatic ghrelin only when they were on MCTD, presumably due to the lack of machinery providing octanoyl acid for acylation in ␤-cells (2). RIP-GG Tg mice have normal glucose tolerance and insulin secretion in the absence of STZ (2) . All experimental procedures were approved by the Kyoto University Graduate School of Medicine Committee on Animal Research.
STZ treatment. Seven-week-old male mice were randomly assigned to vehicle or STZ groups. STZ (100 mg/kg body wt in 100 mM citrate buffer, pH 4.5; Sigma-Aldrich, St. Louis, MO) or vehicle alone was injected after overnight fasting.
Blood glucose levels were determined by the glucose oxidase method using a Glutest sensor (Sanwa Kagaku, Kyoto, Japan), and serum insulin levels were determined using an Ultrasensitive Plus Mouse Insulin kit or a High-Range Speedy Mouse Insulin kit (Morinaga, Yokohama, Japan).
Real-time quantitative RT-PCR. Total RNA was extracted from pancreata using an RNeasy Protect minikit (Qiagen, Hilden, Germany). Reverse transcription (RT) was performed using a high-capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA). Realtime quantitative PCR was performed on an ABI PRISM 7500 Sequence Detection System (Applied Biosystems) using the following primers and TaqMan probes: mouse ghrelin, sense 5=-GCATGCTCGGATGGA-CATG-3=, antisense 5=-TGGTGGCTTCTTGGATTCCT-3=; TaqMan probe 5=-AGCCCAGAGCACCAGAAAGCCCA-3=; mouse insulin 1, sense 5=-CAGCTATAATCAGAGACCATCAGCAA-3=, antisense 5=-GGGTAGGAAGTGCACCAACAG-3=; TaqMan probe 5=-CAGGT-CATTGTTTCAAC-3=; mouse Pdx1, sense 5=-CAAAGCTCAC-GCGTGGAA-3=, antisense 5=-TGTAGGCAGTACGGGTCCTCTT-3=; TaqMan probe 5=-AGGAGGTGCTTACAC-3=; mouse GHS-R, sense 5=-CTGCTCACCGTGATGGTATG-3=, antisense 5=-CAGCAGAG-GATGAAAGCAAA-3=, with Power SybrGreen. Data were normalized to the 18S rRNA content in each sample.
Pancreatic insulin concentration. To measure pancreatic insulin concentration, pancreata were obtained from the mice under the ether anesthesia and homogenized in acid-ethanol. The supernatants were used for assay after centrifugation.
Immunohistochemistry. Formalin-fixed, paraffin-embedded tissue sections were immunostained using the avidin-biotin peroxidase complex method (Vectastain ABC Elite Kit; Vector Laboratories, Burlingame, CA) as described previously (14) . Serial sections (5 m) were incubated with anti-insulin antibody (1:500; DAKO, Glostrup, Denmark). Counterstaining was performed with Mayer's hematoxylin.
Quantitative evaluations of insulin ϩ areas were performed using WinROOF (Mitani, Fukui, Japan). For each pancreas, insulin ϩ areas and islets were evaluated using five sections spaced more than 40 m apart. ϩ cells/area of necrotic ␤-cells.
Statistical analyses.
All values are expressed as means Ϯ SE. The statistical significance of differences in mean values was assessed by Student's t-test. Differences where P Ͻ 0.05 were considered significant. Statistical analyses were performed using Statcel2 (OMS, Saitama, Japan).
RESULTS
Glucose metabolism and insulin secretion in RIP-GG Tg mice treated with STZ.
When RIP-GG Tg mice and their non-Tg littermates were fed a diet of MCTD and treated with STZ, blood glucose levels were significantly elevated in both groups at 7 and 14 days posttreatment compared with vehicle-treated mice (Fig. 1A) , and body weights were significantly decreased in both groups at 7 and 14 days posttreatment compared with vehicle-treated mice (Fig.  1B) . At 14 days posttreatment, serum insulin levels were significantly decreased in STZ-treated mice, and when compared between genotypes, the insulin levels were significantly higher in RIP-GG Tg mice than in non-Tg littermates ( Fig. 1D ), although only the tendency was observed at 7 days posttreatment (Fig. 1C) . The glucose levels in RIP-GG Tg mice, however, were not improved even at 14 days post treatment (Fig. 1A) .
Insulin mRNA expression and ␤-cell numbers in RIP-GG Tg mice treated with STZ. The pancreatic insulin 1 and PDX-1 mRNA levels were not changed in RIP-GG Tg mice 7 days after STZ treatment but were significantly elevated in RIP-GG Tg mice 14 days after STZ treatment, with increased tendency in pancreatic insulin contents (Fig. 2, A 
, B, E).
Pancreatic ghrelin mRNA levels were increased ϳ70-fold in RIP-GG Tg mice compared with their non-Tg littermates (Fig. 2C) . The pancreatic GHS-R mRNA levels were not changed with STZ treatment and were not different between the genotypes (Fig.  2D ). We assessed ␤-cell numbers in the islets of RIP-GG Tg mice 7 and 14 days after STZ treatment (Fig. 3 ). In accord with the insulin mRNA levels, the ratio of insulin ϩ cell area per islet was significantly higher in RIP-GG Tg mice than in their non-Tg littermates 14 days after STZ treatment (Fig. 3, D and  E) , although the restoration of ␤-cell area was limited, considering the fact that the ␤-cell area in vehicle-treated RIP-GG Tg mouse was 83.7 Ϯ 0.67% and that of their non-Tg littermates was 82.9 Ϯ 0.74% (Fig. 3G ). And the difference was not observed without STZ treatment (␤-cell areas on day 0: RIP-GG Tg vs. non-Tg: 88.9 Ϯ 0.71 vs. 87.6 Ϯ 0.99%, P ϭ 0.29), as reported previously (2) . The number of insulin ϩ cells per islet was also significantly higher in RIP-GG Tg mice than in vehicle-treated control animals 14 days after STZ treatment (Fig. 3F ). These differences were not observed 7 days after STZ treatment (Fig. 3, A-C (Fig. 4 , A-D) but were significantly higher in the islets of RIP-GG Tg mice 14 days after STZ treatment (Fig. 4,  E-H) , indicating that ␤-cell proliferation had increased in these animals at 14 days posttreatment.
Short-term effects of STZ treatment: residual ␤-cell numbers and apoptotic index in islets of RIP-GG tg mice.
Finally, we attempted to elucidate whether overexpressed ghrelin had direct protective effects on ␤-cells against STZ treatment. Since we could not detect any TUNEL-positive cells or cleaved caspase-3-positive cells in the islets 14 days after STZ treatment (data not shown), we examined residual ␤-cells and the apoptotic index in islets of RIP-GG Tg mice soon after STZ administration. One day postadministration of the drug, cell nuclei in the islet core were diminished; however, strong immunoreactivity for insulin was still broadly observed, probably due to leakage of insulin from damaged ␤-cells (Fig. 5A) . This artifact made it difficult to accurately determine the number of residual ␤-cells. As an alternative, we assessed insulin mRNA levels in the pancreas of RIP-GG Tg mice before and 1 day after treatment. The pancreatic insulin mRNA levels were significantly decreased in both groups 1 day posttreatment, and there was no difference in insulin mRNA levels between the genotypes, indicating that ␤-cell destruction by STZ was not affected by overexpressed ghrelin (Fig. 5B ). In addition, to determine whether the apoptotic cells were increased, we assessed TUNEL and cleaved caspase-3 expression in islets from RIP-GG Tg mice. The ratio of TUNEL ϩ cell or cleaved caspase-3 ϩ cell number per islets area was not significantly different from that of their non-Tg littermates (Fig. 5, C-F) .
DISCUSSION
In this study, we found that overexpression of intraislet ghrelin ameliorated insulin secretion in an STZ-induced diabetic mouse model by stimulating the proliferation of ␤-cells in the islets. This finding is in accord with our previous reports that exogenous ghrelin administration stimulates ␤-cell proliferation in STZ-treated neonate rats (13) . In the previous study, it was not clear whether the stimulatory effects of ghrelin on ␤-cells were direct or indirect. We hypothesized that indirect mechanisms could be mediated through ghrelin's GH-stimulating and/or orexigenic properties. Here, by using RIP-GG Tg mice, in which intraislet ghrelin levels are elevated without major changes in plasma ghrelin levels (2), we clearly demonstrated that ghrelin directly stimulated ␤-cell proliferation in vivo after STZ treatment.
Although serum insulin levels were elevated in STZ-treated RIP-GG Tg mice, glucose levels were not improved to the degree observed in ghrelin-treated neonate STZ rats (13) . The relatively weak effect observed in this study may have been due to the differences in age and species compared with the previous study. In rats, ␤-cell numbers continue to increase after birth and reach a steady-state level at weaning (10) . Accordingly, in the neonate STZ-treated rat model, ␤-cell numbers recover to some degree even without any therapeutic treatment, and elevated glucose levels temporally return to normal for several weeks after STZ administration (30) . Here, we used adult mice with limited capacity for ␤-cell proliferation (10). Since RIP-GG Tg mice must be fed MCTD in order to increase islet ghrelin levels, we could not study the mice before weaning. The age-related differences in ␤-cell proliferative capacities may explain the disparities in the intensity of ghrelin activity between the current study and the previous report. Another possibility is that the differences reflect species-specific variations. ␤-Cell sensitivity to STZ is known to be different among species (31) . For example, rats are more sensitive than mice to the effects of the drug (31). This difference in STZ sensitivity may have affected the results of these studies. Age and species differences aside, we cannot completely rule out the possibility that exogenously administered ghrelin may have exhibited both direct and indirect effects on ␤-cells in the neonate rat STZ model. At least the current levels of overexpression of ghrelin in the islets seemed not to have enough power to improve the glucose tolerance in adult STZ mouse model. Ghrelin is reported to stimulate the proliferation of several cell lines, including the pancreatic cancer cell line PANC1 (9), the somatotroph cell line GH3 (21), the prostate cancer cell line PC3 (15) , and osteoblasts (19) . Conversely, the peptide has been observed to inhibit the growth of tumors and tumorderived cell lines including human breast carcinoma (6) and fetal thyroid and thyroid follicular tumors (28) . Thus, our results are in accord with previous reports that ghrelin can stimulate cell proliferation. Given that ␤-cell proliferation is not increased at a basal state in RIP-GG Tg mice (2), the proliferative effects of ghrelin on ␤-cells seem to be limited. ␤-Cell proliferation is enhanced in STZ- (30) or alloxan-treated rodents (29) in a partially pancreatectomized rat (4) and in a ductally ligated hamster (23) . However, the mechanisms underlying the stimulation of ␤-cell proliferation in these injury models have not yet been completely elucidated. Ghrelin may synergize with these injury-derived proliferative effects on ␤-cells. Further studies will be needed to clarify the precise mechanisms by which ghrelin stimulates ␤-cell proliferation.
Several lines of evidence suggest that ghrelin can exhibit antiapoptotic effects on a variety of cell types (1, 7, 12, 16, 17) . With respect to ␤-cells, Granata et al. (12) reported that ghrelin prevented apoptosis in the ␤-cell lines HIT-T15 and INS-1E, as well as in human islets. By contrast, in this study we could not detect differences in the apoptotic index of the islets between RIP-GG Tg and control mice. The discrepancy between the previous results and this study may be due to differences in experimental conditions. For example, Granata et al. used ␤-cell lines and isolated islets in vitro and induced apoptosis by serum starvation or the addition of interferons (12), whereas we used an in vivo STZ-induced diabetic mouse model. Furthermore, it has been reported that low doses of STZ induce ␤-cell apoptosis, whereas high doses cause ␤-cell necrosis (24) . In this study, we used 100 mg/kg, which is a relatively high dose. Therefore, although we detected very few apoptotic cells in RIP-GG Tg islets, on the basis of these results we cannot determine whether ghrelin directly protected ␤-cells from apoptosis.
The results of this study indicate that introduction of ghrelin and GOAT to ␤-cells may have beneficial effects on diabetes in the sense that it may increase ␤-cell mass. On the other hand, previous reports indicate that exogenous ghrelin administration suppresses insulin secretion and elevates blood glucose level and that inhibition of ghrelin or GOAT ameliorates glucose tolerance in mice by enhancing insulin secretion (3, 26, 32) . Considering that RIP-GG Tg mice have normal glucose tolerance and insulin secretion, the level of ghrelin needed to stimulate ␤-cell proliferation after STZ-induced ␤-cell injury seems to be lower than the level to suppress insulin secretion. It would be necessary to keep in mind the deleterious side of ghrelin's effect on ␤-cells when therapeutic application of ghrelin on ␤-cell injury is considered.
One drawback of this study is that ghrelin may be produced in tissues other than the ␤-cell, such as hypothalamus, as is the case in the RIP-Cre mice (8) , which may have affected ␤-cell proliferation. Actually, the mRNA levels of ghrelin and GOAT were elevated in the hypothalamus of RIP-GG Tg mice (2) . However, when we examined the expression of the peptide by immunohistochemistry, we found no apparent differences of the ghrelin-like immunoreactivities in the hypothalamus between Tg mice and controls (data not shown). Furthermore, there were no differences in body weight between two groups. Therefore, we doubt that physiologically meaningful levels of ghrelin were produced in the hypothalamus of RIP-GG Tg mice. Nonetheless, we cannot completely eliminate the possibility that the leakage expression of ghrelin in other tissues may have also affected the ␤-cell proliferation indirectly.
In conclusion, we found that serum insulin levels, ␤-cell numbers and ␤-cell proliferation were significantly elevated in RIP-GG Tg mice after STZ treatment without amelioration in glucose levels. These results indicate that ghrelin can directly stimulate ␤-cell proliferation in vivo after ␤-cell injury even without its orexigenic or GH-stimulating activities, although it did not have enough impact to normalize the glucose tolerance in adult mice.
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